- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
How Drug Cost Influences Drug Selection
Zachary T. Bloomgarden, MD, MACE: Very few of my patients are sufficiently wealthy and have sufficiently wonderful managed care pharmacy benefit plans [such] that they can take any drug under the sun and I don’t have to worry about it.
For most individuals with diabetes, we have to realize that they’re taking 1 or 2 lipid-lowering drugs, 2 or 3 diabetes drugs, 2 or 3 blood pressure drugs, often a low-dose aspirin, [and] often a proton-pump inhibitor (although we’re learning that these have some undesirable effects). Often, because of the very high prevalence of anxiety and depression, they take psychoactive drugs. So, these are individuals [who] are not just treated with 1 drug, but they take multiple therapeutic agents.
So, cost is, of course, an issue. If you have a drug that costs $500 or $600 a month, and you expect an individual with diabetes to buy 5 or 6 of them, we’re probably going to be outside the range [within which] that individual can afford [treatment]. [Therefore], we always work very hard with managed care. We work very hard with the patient, but we have to realize that there simply are some cheap drugs that turn out to have a lot of side effects. My personal perspective is that sulfonylureas and NPH (neutral protamine Hagedorn) insulin are drugs that should not be used for treatment of type 2 diabetes.
AI in Health Care: Closing the Revenue Cycle Gap
April 1st 2025This commentary explores the current state, challenges, and potential of artificial intelligence (AI) in health care revenue cycle management, emphasizing collaboration, data standardization, and targeted implementation to enhance adoption.
Read More
Managed Care Reflections: A Q&A With Hoangmai H. Pham, MD, MPH
April 1st 2025To mark the 30th anniversary of The American Journal of Managed Care® (AJMC®), each issue in 2025 will include a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The April issue features a conversation with Hoangmai H. Pham, MD, MPH, a member of AJMC’s editorial board and the president and CEO of the Institute for Exceptional Care (IEC).
Read More
Bridging Care Gaps With a Systemwide Value-Based Care Strategy
March 29th 2025Mapping care management needs by defining patient populations and then stratifying them according to risk and their needs can help to spur the transformation of a siloed health care system into an integrated system that is able to better provide holistic, value-based care despite the many transitions that continue among hospital, primary, specialty, and community care environments.
Read More
